First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Conditions:   Solid Tumor, Adult;   FGFR2 Amplification;   FGFR2 Gene Mutation;   FGFR2 Gene Rearrangement;   FGFR2 Gene Translocation;   FGFR2 Gene Activation;   Intrahepatic Cholangiocarcinoma;   Cholangiocarcinoma;   Endometrial Cancer;   Gastric Cancer;   Breast Cancer Intervention:   Drug: RLY-4008 Sponsor:   Relay Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials